Navigation Links
Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
Date:2/5/2009

PRINCETON, N.J., Feb. 5 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, today announced the publication of data from a phase I/II study of nonpegylated liposomal doxorubicin (Myocet(R)) in the January 1 issue of Clinical Cancer Research. The study was supported by a grant from Roche and was conducted by the Spanish Breast Cancer Cooperative Group (SOLTI).

The study results suggest that Myocet(R), in combination with the approved trastuzumab (Herceptin(R)) plus paclitaxel (Taxol) treatment regimen, yielded an unusually high clinical response rate in patients with HER-2 overexpressing breast cancer. The 3-drug combination was well tolerated. There were no cases of treatment-related symptomatic congestive heart failure. This is noteworthy because cardiotoxicity is a common and therapy-limiting adverse event of the anthracycline class of anti-cancer agents and because Herceptin(R) has its own, well recognized, potential for cardiac toxicity.

Myocet is a liposomal delivery system for doxorubicin designed to reduce the risk of cardiotoxicity associated with doxorubicin while preserving its antitumor efficacy. It is currently in Phase III development in the United States for the treatment of advanced breast cancer.

"These clinical results are encouraging because they suggest that use of a nonpegylated liposomal anthracycline, such as Myocet, may provide important therapeutic benefits, while diminishing cardiac toxicity," said Ronald H. Goldfarb, Ph.D., President and CEO of Sopherion Therapeutics. "Moreover, the incidence of hand foot syndrome, a rate limiting toxicity of other liposomal anthracyclines, is rare with nonpegylated liposomal anthracyclines. We look forward to reporting additional data from ongoing Myocet clinical trials, which further test this concept in patients with advanced breast cancer."<
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
2. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
3. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
4. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
5. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
6. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
7. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
8. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
9. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
11. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... balances – 4 steps – One Recommendation: the web-based ... narrows down the mass of product choices to a ... , First, select the working environment, then enter the ... define the accuracy – it’s really that simple. Specifying ... to models that fit best with the customer’s industry ...
(Date:7/24/2014)... 2014 Draper University, a top ... to announce that for 6 weeks this summer, ... converge on the Draper University campus in the ... program focused on entrepreneurship, building real-world skills, and ... running its sixth cohort, continues to refresh its ...
(Date:7/24/2014)... 2014   Cypher Genomics, Inc., the ... Adam Simpson as president and chief ... comprehensive annotation and interpretation of individual human genomes ... "Cypher,s technology has the potential to play a ... accuracy, optimizing therapeutic approaches and reducing adverse drug ...
(Date:7/24/2014)... Diego, CA (PRWEB) July 24, 2014 ... the reporting of molecular diagnostic test results. It ... capabilities necessary for the validation and reporting of ... oncology. Molecular diagnostics is a rapidly growing area ... infectious disease, genetic predisposition, cancer, and companion diagnostics ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2
... BRUNSWICK, N.J., Feb. 18 Senesco Technologies, Inc. ... financial results for the three months ended December 31, 2008. ... 2008 was $1,624,341, or $0.09 per share, compared with a ... three month period ended December 31, 2007. This increase ...
... a,biotechnology company focused on novel therapeutic and preventative,approaches ... of an EUR18M ($23M) Series B financing round ... operational and clinical level. Novartis Venture Fund,Fountain Healthcare ... all participated in the funding. , ...
... more light than heat. Engineers working in optical technologies ... with much greater speed than do electrical signals, says ... Bethlehem, Pa. If they are guided with sufficient precision ... can bring about applications in spectroscopy, sensing and medical ...
Cached Biology Technology:Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 2Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 3Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 4Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 5Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 6Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 7Opsona Therapeutics Closes EUR18M Funding 2Opsona Therapeutics Closes EUR18M Funding 3Opsona Therapeutics Closes EUR18M Funding 4Engineers tune a nanoscale grating structure to trap and release a variety of light waves 2Engineers tune a nanoscale grating structure to trap and release a variety of light waves 3
(Date:7/24/2014)... in German . ... they are a common sight on the roads of the ... the list of new vehicle registrations for the second time. ... where electric vehicles claim only a small portion of the ... Germany, only a mere 8000 are electric powered. The main ...
(Date:7/24/2014)... inside your gut that has gone undetected by scientists ... San Diego State University has found that more than ... described virus, named crAssphage, which infects one of the ... This phylum of bacteria is thought to be connected ... appears today in Nature Communications ., Robert A. ...
(Date:7/23/2014)... Protection Agency (EPA) today announced that environmental health ... Amherst School of Public Health and Health Sciences ... Achieve Results (STAR) grant to measure indoor air ... in subarctic North America to determine possible health ... culturally-relevant recommendations for mitigation. , Peltier, who will ...
Breaking Biology News(10 mins):Nano-supercapacitors for electric cars 2Nano-supercapacitors for electric cars 3Newly discovered gut virus lives in half the world's population 2Newly discovered gut virus lives in half the world's population 3Studying impacts of indoor air pollution on tribal communities 2Studying impacts of indoor air pollution on tribal communities 3
... the logic of inheritance in his monastery garden with no ... House. So why couldn,t Darwin have done it too? A ... influences and research focus gave him a viewpoint that prevented ... even in his own work. Darwin,s commitment to ...
... just off the east coast of Australia, picturesque North ... some of the inhabitants of the island,s creeks and ... territorial creatures, explains ecologist Robbie Wilson of the University ... one another, they size each other up in a ...
... HAVEN, FLFresh strawberries. Just the mention of this iconic ... of shortcake, fruity drinks and sweet desserts. Researchers interested ... that "sensory quality" of strawberries, a strong influence on ... of sweetness, aroma, texture, and appearance. The goals ...
Cached Biology News:Why didn't Darwin discover Mendel's laws? 2Crafty Australian crayfish cheat 2Analysis of fresh strawberries reveals consumer preferences 2
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
... technology incorporating the sophisticated DirectDrive architecture ... new Varian NMR System is undeniably ... ,The Varian NMR System features parallel ... channel, providing pulse sequence programming power ...
Biology Products: